Mineralys Therapeutics stockMLYS
Mineralys Therapeutics trades at $15.24, 68.0% below its 52-week high (Nov 12, 2025). The price is below its 50- and 200-day averages, a downtrend. −58.0% year to date, −61.6% over 12 months (S&P 500 over the same period: +8.8%). Next earnings report: Mar 18, 2027.
Ratings, candles, signals and the screener for MLYS — after you log in
Open the terminalFrequently asked questions about Mineralys Therapeutics
What is the Mineralys Therapeutics stock price?
At the close on Nov 5, 2026: $15.24 (−10.35% on the day). 52-week high: $47.65 on Nov 12, 2025. During the session the price is updated with a 15-minute delay, after the close with the day's final figures.
When does Mineralys Therapeutics report earnings?
The next quarterly report is on Mar 18, 2027. Last quarter, earnings per share changed −23% year over year, revenue 0%.
Does Mineralys Therapeutics pay dividends?
No, Mineralys Therapeutics does not pay dividends.
Where does Mineralys Therapeutics trade and how to buy it?
Ticker MLYS, exchange Nasdaq, listed since 2023. You can buy it through a broker with access to US exchanges.
Should I buy Mineralys Therapeutics now?
We do not give buy or sell advice. Ratings, the detailed chart and signals for MLYS are in the terminal after you log in.